keyword
MENU ▼
Read by QxMD icon Read
search

palonosetron

keyword
https://www.readbyqxmd.com/read/27889278/safety-and-efficacy-of-nepa-an-oral-fixed-combination-of-netupitant-and-palonosetron-in-older-patients
#1
Matti Aapro, Karin Jordan, Richard J Gralla, Giada Rizzi, Giorgia Rossi, Marco Palmas, Anna V Alyasova, Alla S Lisyanskaya, Snežana M Bošnjak, Paul J Hesketh
OBJECTIVES: Prevention of chemotherapy-induced nausea and vomiting is critical in older cancer patients. NEPA is an oral fixed combination of netupitant 300mg, a new NK1 receptor antagonist (RA), and palonosetron 0.5mg, a pharmacologically distinct 5-HT3 RA. This retrospective analysis evaluated the efficacy and safety of NEPA in older patients. METHODS: Patients aged ≥65 and ≥70years from one phase II and two phase III trials were considered. Chemotherapy-naive patients with malignant tumors were treated with anthracycline-cyclophosphamide (AC), non-AC-based moderately emetogenic chemotherapy (non-AC MEC), or highly emetogenic chemotherapy (HEC)...
November 23, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27885469/nepa-a-fixed-oral-combination-of-netupitant-and-palonosetron-improves-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-over-multiple-cycles-of-chemotherapy-results-of-a-randomized-double-blind-phase-3-trial-versus-oral-palonosetron
#2
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona-Huerta, Vincent Hansen, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Hope Rugo
PURPOSE: Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. NEPA showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with oral PALO in a single chemotherapy cycle; maintenance of efficacy/safety over continuing cycles is the objective of this study...
November 24, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27873176/palonosetron-aprepitant-and-dexamethasone-for-prevention-of-nausea-and-vomiting-after-high-dose-melphalan-in-autologous-transplantation-for-multiple-myeloma-a-phase-ii-study
#3
Atsushi Isoda, Rie Saito, Fuminori Komatsu, Yuki Negishi, Noriyasu Oosawa, Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, Akihiro Manaka
Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous stem cell transplantation (ASCT). We evaluated the efficacy and safety of a triple antiemetic combination of palonosetron, aprepitant, and low-dose dexamethasone in 24 MM patients who received melphalan conditioning (100 mg/m(2) on days 1-2) before ASCT (on day 4). Intravenous palonosetron (0.75 mg on day 1), oral aprepitant (125 mg on day 1; 80 mg on days 2-4), and intravenous dexamethasone (6...
November 21, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27871581/erratum-to-efficacy-of-palonosetron-in-postoperative-nausea-and-vomiting-ponv-a-meta-analysis-j-clin-anesth-2016-34-459-482
#4
Preet Mohinder Singh, Anuradha Borle, Divakara Gouda, Jeetinder Kaur Makkar, Mahesh K Arora, Anjan Trikha, Ashish Sinha, Basavana Goudra
No abstract text is available yet for this article.
December 2016: Journal of Clinical Anesthesia
https://www.readbyqxmd.com/read/27826967/palonosetron-induced-anaphylaxis-during-general-anesthesia-a-case-report
#5
Hyungjun Park, Kyunghwan Oh, Hoonhee Lee, Ji Hyang Lee, Sun Myoung Kang, So Young Park, Hyouk Soo Kwon, You Sook Cho, Hee Bom Moon, Tae Bum Kim
Palonosetron is a 5-hydroxytryptamine-3 (5-HT-3) receptor antagonist used for preventing postoperative nausea and vomiting. Compared with ondansetron and granisetron, it is a better drug because of prolonged action and minimal side effects. Some adverse effects of palonosetron have been reported. In this report, we describe a 37-year-old male who developed severe hypersensitivity reactions to palonosetron during surgery for kidney donation. His medical history was unremarkable, except for inguinal hernia with herniorrhaphy 8 years ago...
January 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/27816008/in-silico-investigation-into-the-interactions-between-murine-5-ht3-receptor-and-the-principle-active-compounds-of-ginger-zingiber-officinale
#6
Anna E Lohning, Wolfgang Marx, Liz Isenring
Gingerols and shogaols are the primary non-volatile actives within ginger (Zingiber officinale). These compounds have demonstrated in vitro to exert 5-HT3 receptor antagonism which could benefit chemotherapy-induced nausea and vomiting (CINV). The site and mechanism of action by which these compounds interact with the 5-HT3 receptor is not fully understood although research indicates they may bind to a currently unidentified allosteric binding site. Using in silico techniques, such as molecular docking and GRID analysis, we have characterized the recently available murine 5-HT3 receptor by identifying sites of strong interaction with particular functional groups at both the orthogonal (serotonin) site and a proposed allosteric binding site situated at the interface between the transmembrane region and the extracellular domain...
October 26, 2016: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/27795228/neurokinin-1-receptor-antagonist-based-triple-regimens-in-preventing-chemotherapy-induced-nausea-and-vomiting-a-network-meta-analysis
#7
REVIEW
Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
BACKGROUND: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. METHODS: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases...
February 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27746523/palonosetron-and-granisetron-in-postoperative-nausea-vomiting-a-randomized-double-blind-prospective-study
#8
Amrita A Gugale, Pradnya Milind Bhalerao
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common occurrence after laparoscopic surgeries. A number of pharmacological agents (antihistamines, butyrophenones, dopamine receptor antagonists) have been tried of which the 5-hydroxytryptamine type 3 receptor antagonists are devoid of most side effects and highly effective in prevention and treatment of PONV. Thus, we evaluated the effectiveness of granisetron and palonosetron in prevention of PONV after laparoscopic surgeries under general anesthesia...
September 2016: Anesthesia, Essays and Researches
https://www.readbyqxmd.com/read/27738796/a-randomized-trial-of-olanzapine-versus-palonosetron-versus-infused-ondansetron-for-the-treatment-of-breakthrough-chemotherapy-induced-nausea-and-vomiting-in-patients-undergoing-hematopoietic-stem-cell-transplantation
#9
Midori Nakagaki, Michael Barras, Cameron Curley, Jason P Butler, Glen A Kennedy
PURPOSE: The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT). METHOD: It was a randomized open-label prospective study. Sixty-two patients were randomized to receive either ondansetron 32-mg infusion over 24 h, or olanzapine wafer 10 mg once daily in addition to ondansetron 8 mg IV three times a day or a single dose of palonosetron 0...
October 13, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27713845/the-first-oral-fixed-dose-combination-of-netupitant-and-palonosetron-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting
#10
Joseph W Coyne
No abstract text is available yet for this article.
January 2016: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/27712113/palonosetron-and-hydroxyzine-pre-treatment-reduces-the-objective-signs-of-experimentally-induced-acute-opioid-withdrawal-in-humans-a-double-blinded-randomized-placebo-controlled-crossover-study
#11
Matthew J Erlendson, Nicole D'Arcy, Ellen M Encisco, Jeffrey J Yu, Lorena Rincon-Cruz, Gary Peltz, J David Clark, Larry F Chu
BACKGROUND: Treatments for reducing opioid withdrawal are limited and prone to problematic side effects. Laboratory studies, clinical observations, and limited human trial data suggest 5-HT3-receptor antagonists and antihistamines may be effective. OBJECTIVES: This double-blind, crossover, placebo-controlled study employing an acute physical dependence model evaluated whether (i) treatment with a 5-HT3-receptor antagonist (palonosetron) would reduce opioid withdrawal symptoms, and (ii) co-administration of an antihistamine (hydroxyzine) would enhance any treatment effect...
August 11, 2016: American Journal of Drug and Alcohol Abuse
https://www.readbyqxmd.com/read/27687434/efficacy-of-palonosetron-in-postoperative-nausea-and-vomiting-ponv-a-meta-analysis
#12
REVIEW
Preet Mohinder Singh, Anuradha Borle, Divakara Gouda, Jeetinder Kaur Makkar, Mahesh K Arora, Anjan Trikha, Ashish Sinha, Basavana Goudra
INTRODUCTION: Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV). METHODS: Randomized controlled trials involving adult population undergoing elective surgery under general anesthesia comparing palonosetron to placebo, ramosetron, granisetron, and ondansetron were included. Data were extracted for vomiting incidence (VI), complete response (no nausea/vomiting; Complete Response [CR]), and rescue antiemetic need...
November 2016: Journal of Clinical Anesthesia
https://www.readbyqxmd.com/read/27677233/-5-ht3-antagonists-as-a-substitute-for-metoclopramide-and-domperidone-a-literature-review
#13
I Mouch, J R B J Brouwers, E van 't Riet, P Nieboer, M H Otten, F G A Jansman
OBJECTIVE: To investigate whether the anti-emetics metoclopramide and domperidone can be replaced by 5-HT3-antagonists, as side effects restrict use of these dopamine antagonists. DESIGN: Systematic review. METHOD: We searched the Embase and PubMed databases for articles published in the period 1995-October 2015, in which the efficacy or side effects of metoclopramide or domperidone were compared with at least one of the 5-HT3-antagonists ondansetron, granisetron, tropisetron or palonosetron...
2016: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/27666343/combination-of-palonosetron-aprepitant-and-dexamethasone-effectively-controls-chemotherapy-induced-nausea-and-vomiting-in-patients-treated-with-concomitant-temozolomide-and-radiotherapy-results-of-a-prospective-study
#14
Masahide Matsuda, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroyoshi Akutsu, Shingo Takano, Akira Matsumura
Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration. In a previous study, we showed not only higher incidence rates of chemotherapy-induced nausea and vomiting (CINV) during the overall study period, but also substantially higher incidence rates of moderate/severe nausea and particularly severe appetite suppression during the late phase of the treatment. Here, we prospectively evaluated the efficacy of a combination of palonosetron, aprepitant, and dexamethasone for CINV in patients treated with concomitant TMZ and radiotherapy...
November 15, 2016: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/27650295/a-randomized-double-blind-trial-evaluating-the-efficacy-of-palonosetron-with-total-intravenous-anesthesia-using-propofol-and-remifentanil-for-the-prevention-of-postoperative-nausea-and-vomiting-after-gynecologic-surgery
#15
Yun-Sic Bang, Young Uk Kim, Dawoon Oh, Eui Yong Shin, Soo Kyoung Park
PURPOSE: Palonosetron has potent and long-acting antiemetic effects for postoperative nausea and vomiting (PONV). The aim of this study was to prospectively evaluate the efficacy of palonosetron when used with total intravenous anesthesia (TIVA) using propofol and remifentanil for the prevention of PONV in patients undergoing laparoscopic gynecologic surgery. METHODS: This prospective double-blind study comprised 100 female American Society of Anesthesiologist physical status I and II patients who were undergoing laparoscopic gynecologic surgery under TIVA...
September 20, 2016: Journal of Anesthesia
https://www.readbyqxmd.com/read/27636144/comparison-of-the-prophylactic-antiemetic-efficacy-of-aprepitant-plus-palonosetron-versus-aprepitant-plus-ramosetron-in-patients-at-high-risk-for-postoperative-nausea-and-vomiting-after-laparoscopic-cholecystectomy-a-prospective-randomized-controlled-trial
#16
Eun Kyung Choi, Dong Gyeong Kim, Younghoon Jeon
We compared the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in patients after laparoscopic cholecystectomy. A total of 88, nonsmoking, female patients undergoing laparoscopic cholecystectomy were randomly allocated to 2 groups of 44 each who received palonosetron 0.075 mg (aprepitant plus palonosetron group) and ramosetron 0.3 mg (aprepitant plus ramosetron group) after induction of anesthesia. All patients received aprepitant 80 mg 2 hours before surgery. The incidence of postoperative nausea and vomiting (PONV), use of rescue antiemetic, pain severity, and any side effects were assessed for 24 hours after surgery...
October 2016: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
https://www.readbyqxmd.com/read/27630563/profile-of-antiemetic-activity-of-netupitant-alone-or-in-combination-with-palonosetron-and-dexamethasone-in-ferrets-and-suncus-murinus-house-musk-shrew
#17
John A Rudd, Man P Ngan, Zengbing Lu, Guy A Higgins, Claudio Giuliano, Emanuela Lovati, Claudio Pietra
BACKGROUND AND AIMS: Chemotherapy-induced acute and delayed emesis involves the activation of multiple pathways, with 5-hydroxytryptamine (5-HT; serotonin) playing a major role in the initial response. Substance P tachykinin NK1 receptor antagonists can reduce emesis induced by disparate emetic challenges and therefore have a clinical utility as broad inhibitory anti-emetic drugs. In the present studies, we investigate the broad inhibitory anti-emetic profile of a relatively new NK1 receptor antagonist, netupitant, alone or in combination with the long acting 5-HT3 receptor antagonist, palonosetron, for a potential to reduce emesis in ferrets and shrews...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27612464/a-prospective-study-of-the-antiemetic-effect-of-palonosetron-in-malignant-lymphoma-patients-treated-with-the-chop-regimen
#18
Yoshiharu Miyata, Kimikazu Yakushijin, Yumiko Inui, Yoshinori Imamura, Hideaki Goto, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yukinari Sanada, Yosuke Minami, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Ryo Tominaga, Hiroshi Gomyo, Ishikazu Mizuno, Tetsuhiko Nomura, Koichi Kitagawa, Takeshi Sugimoto, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication...
September 9, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27591991/role-of-olanzapine-in-chemotherapy-induced-nausea-and-vomiting-on-platinum-based-chemotherapy-patients-a-randomized-controlled-study
#19
Sandip Mukhopadhyay, Gagandeep Kwatra, Pamela Alice K, Dinesh Badyal
PURPOSE: Even with the use of modern antiemetic drugs, chemotherapy-induced nausea and vomiting (CINV) is still a cause of great distress to the patients. Olanzapine, primarily marketed as an antipsychotic, was found to reduce nausea and vomiting in some chemotherapy patients. But it was never tested in Indian population with a diverse genetic background. The present study aims to evaluate the role of olanzapine in CINV in patients receiving platinum-based chemotherapy. METHODS: The study was a randomized, controlled, assessor-blinded study on 100 chemotherapy-naïve consenting patients receiving any one from cisplatin, carboplatin or oxaliplatin...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27583032/neurokinin-1-inhibitors-in-the-prevention-of-nausea-and-vomiting-from-highly-emetogenic-chemotherapy-a-network-meta-analysis
#20
REVIEW
Omar Abdel-Rahman
A network meta-analysis of the comparative effectiveness of neurokinin 1 (NK-1) inhibitors in the prophylaxis of highly emetogenic chemotherapy induced nausea and vomiting has been conducted. Eligible studies included randomized trials evaluating aprepitant, fosaprepitant, netupitant (NEPA), casopitant and rolapitant containing regimens in the setting of highly emetogenic chemotherapy. Primary outcomes of interest include complete response (CR) and rate of no significant nausea. After preclusion of ineligible studies, 19 studies were included in the final analysis...
September 2016: Therapeutic Advances in Medical Oncology
keyword
keyword
97546
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"